Molecular markers predicting disease outcome in bladder cancer. Should we shift from the classical cell-cycle regulators to HER2 oncogene?| JOURNAL OF GERONTOLOGY AND GERIATRICS
Vol. 66: SPECIAL ISSUE 4 - DICEMBER 2018 - Urologic problems in elderly patient
Clinical Geriatrics - Reviews
Published: 2018-12-15
PDF

Molecular markers predicting disease outcome in bladder cancer. Should we shift from the classical cell-cycle regulators to HER2 oncogene?

Section of Pathology, Department of Clinical and Experimental Medicine, University of Foggia, Italy
Department of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari, Italy
Urology and Renal Transplantation Unit, Department of Medical and Surgical Sciences, University of Foggia, Italy
Urology, Humanitas Clinical and Research Hospital, Rozzano, Milan, Italy; Humanitas University, Rozzano, Milan, Italy
Division of Urology, Department of Surgery, VCU Health, Richmond, VA, USA
Urology and Renal Transplantation Unit, Department of Medical and Surgical Sciences, University of Foggia, Italy
Molecular marker HER2 Bladder cancer Oncogene

Abstract

Bladder cancer is regarded as a disease of the elderly as its incidence increases steeply with increase in age.
One of the main clinical issues in bladder cancer is predicting disease outcome. Since the unpredictable
behavior of this disease has been attributed to its biology, the search for predictive factors has mainly been
oriented towards molecular markers. Cell-cycle regulators are the most studied ones but there is emerging
evidence that HER2 oncogene, widely studied and used in other cancers, may soon overcome them.
Herein we reviewed available evidence regarding the predictive role of cell-cycle regulators and HER2 oncogene.
Emerging data suggest that HER2, either alone or in combination with other markers, can be equally
if not more effective than cell-cycle regulators in predicting disease outcome. Moreover, it represents a wellknown and particularly attractive potential therapeutic target.

Affiliations

F. Sanguedolce

Section of Pathology, Department of Clinical and Experimental Medicine, University of Foggia, Italy

A. Cormio

Department of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari, Italy

B. Calò

Urology and Renal Transplantation Unit, Department of Medical and Surgical Sciences, University of Foggia, Italy

N. Buffi

Urology, Humanitas Clinical and Research Hospital, Rozzano, Milan, Italy; Humanitas University, Rozzano, Milan, Italy

R. Autorino

Division of Urology, Department of Surgery, VCU Health, Richmond, VA, USA

L. Cormio

Urology and Renal Transplantation Unit, Department of Medical and Surgical Sciences, University of Foggia, Italy

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright

© Società Italiana di Gerontologia e Geriatria (SIGG) , 2018

How to Cite

[1]
Sanguedolce, F., Cormio, A., Calò, B., Buffi, N., Autorino, R. and Cormio, L. 2018. Molecular markers predicting disease outcome in bladder cancer. Should we shift from the classical cell-cycle regulators to HER2 oncogene?. JOURNAL OF GERONTOLOGY AND GERIATRICS. 66, 4 (Dec. 2018), 239-244.
  • Abstract viewed - 115 times
  • PDF downloaded - 68 times